All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AXT107
Therapeutic Area: Ophthalmology Product Name: AXT107
Highest Development Status: Phase I/ Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
AXT107 is an investigational drug candidate that inhibits VEGF-A and VEGF-C and activates Tie2. With its novel mechanisms of action, AXT107 has the potential to be a standard of care monotherapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SAR439483
Therapeutic Area: Ophthalmology Product Name: SAR439483
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sofinnova Investments
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 16, 2020
Details:
Proceeds will be used to advance Atsena’s ongoing Phase I/II clinical trial evaluating a gene therapy for patients with GUCY2D-associated Leber congenital amaurosis (LCA1), as well as complete manufacturing development for Phase 3.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retinal pigment epithelium cells
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retinal pigment epithelial cells
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
OpRegen is an investigational cell therapy consisting of retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TTHX1114
Therapeutic Area: Ophthalmology Product Name: NM141
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
TTHX1114, administered by intracameral injection, is currently undergoing a Phase 1/2 clinical study to assess its safety and ability to regenerate corneal endothelial cells lost due to corneal endothelial dystrophies, including Fuchs endothelial corneal dystrophy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IVMED-80
Therapeutic Area: Ophthalmology Product Name: IVMED-80
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
IVMED-80 is a proprietary non-surgical, non-invasive, disease modifying intervention with FDA orphan designation that upregulates lysyl oxidase (LOX) and induces corneal crosslinking pharmacologically.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AR-15512
Therapeutic Area: Ophthalmology Product Name: AVX012
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The active ingredient in AR-15512 is a potent and selective agonist of the TRPM8 cold thermoreceptor ion channel that regulates tear production and blink rate. The acceptance of the IND for AR-15512 marks the first clinical-stage dry eye product candidate for Aerie.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IVMED-80
Therapeutic Area: Ophthalmology Product Name: IVMED-80
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: National Eye Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series B Financing August 25, 2020
Details:
These investments will be used to advance the clinical development programs for the treatment of keratoconus and pediatric high myopia and adult low myopia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TTHX1114
Therapeutic Area: Ophthalmology Product Name: NM141
Highest Development Status: Phase I/ Phase II
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
